Total Payments
$8,723
2024 Payments
$3,451
Companies
40
Transactions
366
Medicare Patients
1,870
Medicare Billing
$317,148
Payment Breakdown by Category
Food & Beverage$8,696 (99.7%)
Education$26.46 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,696 | 364 | 99.7% |
| Education | $26.46 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,356 | 70 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,024 | 58 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $835.30 | 23 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $625.92 | 25 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $552.07 | 24 | $0 (2024) |
| Mylan Specialty L.P. | $430.64 | 18 | $0 (2024) |
| Insmed, Inc. | $424.99 | 14 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $415.64 | 14 | $0 (2024) |
| GENZYME CORPORATION | $391.86 | 15 | $0 (2024) |
| Axsome Therapeutics, Inc. | $303.48 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,451 | 143 | AstraZeneca Pharmaceuticals LP ($729.32) |
| 2023 | $3,434 | 138 | GlaxoSmithKline, LLC. ($363.00) |
| 2022 | $1,123 | 45 | Harmony Biosciences LLC ($219.17) |
| 2021 | $45.01 | 3 | AstraZeneca Pharmaceuticals LP ($25.85) |
| 2020 | $154.73 | 10 | AstraZeneca Pharmaceuticals LP ($41.24) |
| 2019 | $358.73 | 22 | Boehringer Ingelheim Pharmaceuticals, Inc. ($76.64) |
| 2018 | $58.41 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($35.08) |
| 2017 | $96.83 | 1 | EKOS Corporation ($96.83) |
All Payment Transactions
366 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $31.09 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/10/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $19.61 | General |
| Category: Medical Device | ||||||
| 12/09/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: RESPIRATORY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Respiratory | ||||||
| 11/27/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $34.20 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/26/2024 | Resmed Corp | AIRSENSE (Device) | Food and Beverage | Cash or cash equivalent | $24.08 | General |
| Category: Sleep | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $34.50 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $44.18 | General |
| Category: Narcoplepsy | ||||||
| 11/12/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: NEUROLOGY | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/31/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $29.75 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $1.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,057 | 1,541 | $292,019 | $144,352 |
| 2022 | 2 | 25 | 45 | $17,806 | $6,511 |
| 2021 | 7 | 322 | 525 | $205,615 | $70,220 |
| 2020 | 11 | 466 | 749 | $295,445 | $96,065 |
Total Patients
1,870
Total Services
2,860
Medicare Billing
$317,148
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 163 | 414 | $82,800 | $41,280 | 49.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 63 | 114 | $39,900 | $20,384 | 51.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 103 | 110 | $33,000 | $15,982 | 48.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 68 | 105 | $23,675 | $15,874 | 67.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 100 | $17,500 | $10,800 | 61.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $9,350 | $6,316 | 67.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 87 | $13,050 | $5,767 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 64 | $8,000 | $4,856 | 60.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 111 | 168 | $15,120 | $3,856 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $5,400 | $3,138 | 58.1% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 18 | 33 | $6,550 | $2,966 | 45.3% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 54 | 55 | $6,600 | $2,686 | 40.7% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 52 | 53 | $6,360 | $2,471 | 38.9% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 13 | 13 | $4,524 | $1,982 | 43.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $3,325 | $1,717 | 51.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 50 | 51 | $6,630 | $1,657 | 25.0% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 15 | 15 | $5,730 | $1,336 | 23.3% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 19 | 21 | $1,575 | $598.50 | 38.0% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 16 | 23 | $1,150 | $360.18 | 31.3% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 13 | 13 | $520.00 | $128.18 | 24.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 13 | 13 | $780.00 | $109.98 | 14.1% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 12 | 12 | $480.00 | $88.08 | 18.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 14 | 34 | $16,354 | $5,892 | 36.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 11 | $1,452 | $618.53 | 42.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 133 | 272 | $142,800 | $45,155 | 31.6% |
About Dr. Anthony Flaim, DO
Dr. Anthony Flaim, DO is a Pulmonary Disease healthcare provider based in Stratford, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2011. The National Provider Identifier (NPI) number assigned to this provider is 1851687966.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Flaim, DO has received a total of $8,723 in payments from pharmaceutical and medical device companies, with $3,451 received in 2024. These payments were reported across 366 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($8,696).
As a Medicare-enrolled provider, Flaim has provided services to 1,870 Medicare beneficiaries, totaling 2,860 services with total Medicare billing of $317,148. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Stratford, NJ
- Active Since 06/27/2011
- Last Updated 07/03/2018
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1851687966
Products in Payments
- DUPIXENT (Biological) $1,005
- WAKIX (Drug) $616.13
- TRELEGY ELLIPTA (Drug) $566.21
- FASENRA (Biological) $505.59
- Arikayce (Drug) $424.99
- NUCALA (Biological) $416.47
- XYWAV (Drug) $415.64
- YUPELRI (Drug) $345.12
- AIRSUPRA (Drug) $332.15
- BREZTRI (Drug) $304.00
- Sunosi (Drug) $303.48
- STIOLTO RESPIMAT (Drug) $240.08
- Wakix (Drug) $219.17
- Adempas (Drug) $217.63
- SPIRIVA RESPIMAT (Drug) $192.02
- XARELTO (Drug) $182.30
- Prolastin-C Liquid (Biological) $178.39
- TYVASO (Drug) $174.98
- PURIFIED CORTROPHIN GEL (Drug) $144.08
- TEZSPIRE (Biological) $143.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.